Download PDF
Open Access
CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2018; 54(02): 078-089
DOI: 10.1055/s-0040-1712790
Review Article

Atopic Dermatitis: Drug Delivery (Management) and Approaches (Strategies) in Perspective

Authors

  • Virendra N. Sehgal

    Dermato-Venereology (Skin/VD) Center, Sehgal Nursing Home, Panchwati, Delhi.
Further Information
Also available at
 PDF Download Permissions and Reprints

ABSTRACT

Age-related cutaneous manifestations are definitive pointer to the diagnosis of atopic dermatitis, the confirmation of which is solicited by 3 major and 3 minor criteria. Its unpredictable course is punctuated by exacerbations and remissions. Several treatment options, namely: 1st, 2nd and 3rd line are in vogue ever since. The 1st line envisages general measures, 2nd encompasses topical applications, while the 3rd take into account drug therapy comprising, systemic Corticosteroids, Cyclosporin, Azathioprine, Thymopentin, Interferon–therapy, Topical Calcineurin inhibitors: Tacrolimus and Pimecrolimus. The mode of action, their dosages and adverse drug reaction (ADR), in particular, have been focused in this paper with special attention to refresh their drug delivery (management) approaches (strategies) in perspective. An endeavor to focus attention to emerging etio-pathogenesis, and its application in the contemporary context has also been made.

Keywords:

Atopic dermatitis - Immunoglobulins E - Cyclosporin - Azathioprine - Thymopentin - Interferon-therapy


Publication History

Article published online:
08 May 2020

© .

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Sehgal V N, Srivastava G, Dogra S (2010). Atopic dermatitis: current options and treatment plans. Skinmed 8: 335-344.
  • 2 Staab D, Diepgen TL, Fartasch M, et al (2006). Age-related structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. Br Med J 332: 933–938.
  • 3 Anonymous (2005). Atopic eczema - new insights in the definition, diagnostics and disease management. Proceedings of a LEO eczema workshop. November 2003. Copenhagen, Denmark. Acta Derm Venereol Suppl (Stockh) 215: 7–48.
  • 4 Anonymous (2005). Consensus conference management of atopic dermatitis in children. Recommendations (short version). Eur J Dermatol 15: 215–223.
  • 5 Ishizaka K, Ishizaka T, Hornbrook MM (1966). Physicochemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol 97(1): 75- 85.
  • 6 Winter WE, Hardt NS, Fuhrman S (2000). IgE–importance in parasitic infections and hypersensitivity responses. Arch Pathol Lab Med 124: 1382-1385.
  • 7 Bennich H, Johansson SGO (1971). Structure and function of human Immunoglobulin E. Adv Immunol 13: 1-55.
  • 8 Berg T, Johansson SG (1969). IgE concentrations in children with atopic diseases. Intl Arch Allergy 36: 219-232.
  • 9 Juhlin L, Johansson SGO, Bennich H, et al (1969). IgE in dermatoses. Arch Dermatol 100: 12-16.
  • 10 Varelzidis A, Wilson AB, Meara RH, et al (1966). Immunoglobulin levels in atopic eczema. Br Med J 2: 925-927.
  • 11 Ortiz F (1968). Serum levels of IgAin atopic patients. Allerg Asthma (Leipz) 14:116-122.
  • 12 Tiwari G, Tiwari R, Sriwastawa B, et al (2012). Drug delivery systems: an updated review. Intl J Pharm Investig 2: 2–11.
  • 13 Boguniewicz M, Eichenfield LF, Hultsch T (2003). Current management of atopic dermatitis and interruption of the atopic march. J Allergy Clin Immunol 112: 140-150.
  • 14 George SA, Bilsland DJ, Johnson BE, et al (1993). Narrow-band (TL-01) UVB air-conditioned phototherapy for chronic severe adult atopic dermatitis. Br J Dermatol 128: 49-56.
  • 15 Galli E, Chini L, Moschese V et al (1994). Methylprednisolone bolus1: a novel therapy for severe atopic dermatitis. Acta Paediatr 83: 315-317.
  • 16 Lipozencic J, Wolf R (2007). Atopic dermatitis: an update and review of the literature. Dermatol Clin 25: 605-612.
  • 17 Munro CS, Levell NJ, Shuster S, et al (1994). Maintenance treatment with cyclosporine in atopic dermatitis. Br J Dermatol 130: 376-380.
  • 18 Anonymous (2011). Cyclosporin. Dictionary.com Un-abridged. Random House. n.d. Archived from the original on 2010-11-18. Retrieved 2011-07-13.
  • 19 Cantrell DA, Smith KA (1984). The interleukin-2 T-cell system: a new cell growth model. Science 224: 1312-1316.
  • 20 Wolverton S, Darst M (2003). Systemic drugs. In: Dermatology. Bolognia JL, Jorizzo JL, Rapini RP, eds. Edinburgh (Scotland): Mosby, 2071-2077.
  • 21 Svarstad H, Bugge HC, Dhillion SS (2009). From Norway to Novartis: Cyclosporin from Tolypocladium inflatum in an open access bioprospecting regime. Biodiversity Conservation 9: 1521–1541.
  • 22 Borel JF (2002). History of the discovery of cyclosporin and of its early pharmacological development. Wien Klin Wochenschr 114: 433–437.
  • 23 Denby KS, Beck LA (2012). Update on systemic therapies for atopic dermatitis. Curr Opin Allergy Clin Immunol 12: 421-426.
  • 24 Czech W, Bräutigam M, Weidinger G, Schöpf E (2000). A body-weight independent dosing regimen of cyclosporine microemulsion is effective in severe atopic dermatitis and improves the quality of life. J Am Acad Dermatol 42: 653-659.
  • 25 Robert N, Wong GW, Wright JM (2010). Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev: CD007893.
  • 26 Naesens M, Kuypers DR, Sarwal M (2009). Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4: 481–509.
  • 27 Lear JT, English JS, Jones P, et al (1996). Retrospective review of the use of azathioprine in severe atopic dermatitis. J Am Acad Dermatol 35: 642-643.
  • 28 Azathioprine. Merriam-Webster Dictionary.
  • 29 American Society of Health-System Pharmacists. Azathioprine, Azathioprine Sodium. AHFS Drug Information 2012. American Society of Health-System Pharmacists.
  • 30 Fields CL, Robinson JW, Roy TM, Ossorio MA, Byrd RP Jr (1998). Hypersensitivity reaction to azathioprine. South Med J 91: 471-474.
  • 31 Hsieh KH, Shaio MF, Liao TN (1992). Thymopentin treatment in severe atopic dermatitis--clinical and immunological evaluations. Arch Dis Child 67: 1095-1102.
  • 32 Mascart-Lemone F, Huygen K, Clumeck N, Brenez D, Bolla K, Duchateau J (1983). Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients. Lancet 322: 735–736.
  • 33 Peng Y, Chen Z, Yu W, et al (2008). Effects of thymic polypeptides on the thymopoiesis of mouse embryonic stem cells. Cell Biol Intl 32:1265-1271.
  • 34 Goldstein G, Audhya TK (1985). Thymopoietin to thymopentin: experimental studies. Surv Immunol Res 4 Suppl 1:1-10.
  • 35 Liu Z, Zheng X, Wang J, et al (2007). Molecular analysis of thymopentin binding to HLA-DR molecules. PLoS ONE 2: e1348.
  • 36 Haneke E, Bolla K, Degreef H, et al (1984). The effect of thymopentin treatment on the relapse rate in frequently relapsing herpes simplex virus infections. Intl J Clin Pharmacol Res 4: 439-443.
  • 37 Stiller MJ, Shupack JL, Kenny C, et al (1994). A double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of thymopentin as an adjunctive treatment in atopic dermatitis. J Am Acad Dermatol 30: 597-602.
  • 38 Leung DY, Hirsch RL, Schneider L, et al (1990). Thymopentin therapy reduces the clinical severity of atopic dermatitis. J Allergy Clin Immunol 85: 927-933.
  • 39 Noh GW, Lee KY (1998). Korean thymopentin therapy in atopic dermatitis. J Pediatr 41: 1268-1272.
  • 40 De Weerd NA, Samarajiwa SA, Hertzog PJ (2007). Type I interferon receptors: biochemistry and biological functions. J Biol Chem 282: 20053–20057.
  • 41 De Andrea M, Ravera R, Gioia D, Gariglio M, , Landolfo S (2002). The interferon system: an overview. Eur J Paediatr Neurol 6 Suppl A: A41–A56.
  • 42 Cohen B, Parkin J (2001). An overview of the immune system. Lancet 357: 1777–1789.
  • 43 Wüthrich B, Schmid-Grendelmeier P (2003). The atopic eczema/dermatitis syndrome. Epidemiology, natural course, and immunology of the IgE-associated ("extrinsic") and the nonallergic ("intrinsic") AEDS. J Investig Allergol Clin Immunol 13: 1–5.
  • 44 Schmid-Grendelmeier P, Simon D, Simon HU, et al (2001). Epidemiology, clinical features, and immunology of the "intrinsic" (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 56: 841–849.
  • 45 Reinhold U, Kukel S, Brzoska J, Kreysel HW (1993). Systemic interferon gamma treatment in severe atopic dermatitis. J Am Acad Dermatol 29: 58-63.
  • 46 Chang TT, Stevens SR (2002). Atopic dermatitis: the role of recombinant interferon-gamma therapy. Am J Clin Dermatol 3:175-183.
  • 47 Schneider LC, Baz Z, Zarcone C, Zurakowski D (1998). Long-term therapy with recombinant interferon-gamma (rIFNgamma) for atopic dermatitis. Ann Allergy Asthma Immunol 80: 263-268.
  • 48 Sleijfer S, Bannink M, Van Gool AR, et al (2005). Side effects of interferon-alpha therapy. Pharm World Sci 27: 423-431.
  • 49 Berman B, De Araujo T, Lebwohl M (2003). Immunomodulators. In: Dermatology. Bolognia JL, Jorizzo JL, Rapini RP, eds. Edinburgh (Scotland): Mosby, 2033–2053.
  • 50 Kapp A, Allen BR, Reitamo S (2003). Atopic dermatitis management with tacrolimus ointment. J Dermatol Treat 14: 5–16.
  • 51 Contreras Ruiz J, Kerdel FA (2004). Tacrolimus (FK-506). In: Drug Therapy in Dermatology, 1st edn. Millikan LE, ed. New York NY: Marcel Dekkar Inc, 161-170.
  • 52 Ruzicka T, Bieber T, Schöpf E, et al (1997). A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 337: 816–821.
  • 53 Sehgal VN, Srivastava G, Dogra S (2008). Tacrolimus in dermatology— pharmacokinetics, mechanism of action, drug interactions, dosages, and side effects: part I. Skinmed 7: 27-30.
  • 54 Sehgal VN, Srivastava G, Dogra S (2008). Tacrolimus: approved and unapproved dermatologic indications/uses—physician's sequential literature survey: part II. Skinmed 7: 73-77.
  • 55 Sehgal VN, Pahwa M (2007). Pimecrolimus, yet another intriguing topical immunomodulator. J Dermatolog Treat 18: 147-150.
  • 56 Ashcroft DM, Dimmock P, Garside R, et al (2005). Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. Br Med J 330: 516–522.
  • 57 FDA ( 2006). FDA Approves Updated Labeling with Boxed Warning and Medication Guide for Two Eczema Drugs, Elidel and Protopic P06-09 January 19, 2006 https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyIn formationforPatientsandProviders/ucm1539 41.htm.
  • 58 Shri J, Amichai B (2006). Tacrolimus ointment in the treatment of atopic hand eczema. Indian J Dermatol 51: 66-67.
  • 59 Meurer M, Folster-Holst R, Wozel G, et al (2002). Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 205: 271-277.
  • 60 Billich A, Aschauer H, Aszódi A, Stuetz A (2004). Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Intl J Pharm 269:29-35.
  • 61 Huang X, Xu B (2015). Efficacy and safety of tacrolimus versus pimecrolimus for the treatment of atopic dermatitis in children: a network meta-analysis. Dermatology 231: 41-49.
  • 62 Werfel T (2009). Topical use of pimecrolimus in atopic dermatitis: update on the safety and efficacy. J Dtsch Dermatol Ges 7: 739-742.
  • 63 Lee HH, Zuberbier T, Worm M (2007). Treatment of atopic dermatitis with pimecrolimus – impact on quality of life. Ther Clin Risk Manag 3: 1021–1026.
  • 64 Luger T, Boguniewicz M, Carr W (2015). Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol 26: 306-315.
  • 65 Iraji F, Farhadi S, Faghini G, et al (2015). Efficacy of topical azathioprine and betamethasone versus betamethasone-only emollient cream in 2-18 years old patients with moderate-to-severe atopic dermatitis: a randomized controlled trial. Adv Biomed Res 4: 228.
  • 66 Rerknimitr P, Otsuka A, Nakashima C, Kabashima K (2017). The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regen 37:14. https://doi.org/10.1186/s41232-017-0044-7.
  • 67 Sehgal VN, Khurana A, Mendiratta V, et al (2015). Atopic dermatitis; etio-pathogenesis, an overview. Indian J Dermatol 60: 327-331.
  • 68 Elias PM, Hatano Y, Williams ML (2008). Basis for the barrier abnormality in atopic dermatitis: outside -inside -outside pathogenic mechanisms. J Allergy Clin Immunol 121:1337–1343.
  • 69 Levin J, Friedlander SF, Del Rosso JQ, et al (2013). Atopic dermatitis and the stratum corneum: part 1: the role of filaggrin in the stratum corneum barrier and atopic skin. J Clin Aesthet Dermatol 6: 16–22.
  • 70 Ovaere P, Lippens S, Vandenabeele P, Declercq W (2009). The emerging roles of serine protease cascades in the epidermis. Trends Biochem Sci 34: 453–463.
  • 71 Markova NG, Marekov LN, Chipev CC, et al (1993). Profilaggrin is a major epidermal calcium-binding protein. Mol Cell Biol 13: 613–625.
  • 72 Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al (2006). Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 38: 441-446.
  • 73 Miraglia del Giudice M, Decimo F, Leonardi S, et al (2006). Immune dysregulation in atopic dermatitis. Allergy Asthma Proc 27: 451-455.
  • 74 An update on the genetics of atopic dermatitis: scratching the surface in 2009. J Allergy Clin Immunol 125: 16–31.
  • 75 Schnopp C, Holtmann C, Stock S, et al (2002). Topical steroids under wet-wrap dressings in atopic dermatitis-a vehicle-controlled trial. Dermatology 204: 56–59.
  • 76 Hanifin JM, Hebert AA, Mays SR, et al (1998). Effects of a low -potency corticosteroid lotion plus a moisturizing regimen in the treatment of atopic dermatitis. Curr Ther Res 59(4): 227–233.
  • 77 Anonymous (2007). Atopic Eczema in Children: Management of Atopic Eczema in Children from Birth up to the Age of 12 Years. NICE Clinical Guidelines, No. 57. National Collaborating Centre for Women's and Children's Health (UK). London: RCOG Press.
  • 78 Loden M, Andersson A-C (1996). Effect of topically applied lipids on surfactant irritated skin. Br J Dermatol 134: 215–220.
  • 79 Grimalt R, Mengeaud V, Cambazard F (2007). The steroid sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology (Basel) 214: 61–67.
  • 80 Chamlin SL, Frieden IJ, Fowler A, et al (2001). Ceramide-dominant, barrier-repair lipids improve childhood atopic dermatitis. Arch Dermatol 137: 1110–1112.
  • 81 Thomas KS, Armstrong S, Avery A, et al (2002). Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild to moderate atopic eczema. Br Med J 324: 768–771.
  • 82 Klein PA, Clark RA (1999). An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 135: 1522–1525.
  • 83 Kemp JP (1989). Tolerance to antihistamines: is it a problem? Ann Allergy 63:621–623.
  • 84 Diepgen TL; Early treatment of the Atopic Child Study Group (2002). Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double–blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol 13: 278–286.
  • 85 Lipozencic J, Wolf R (2007). Atopic dermatitis: an update and review of the literature. Dermatol Clin 25: 605–612.
  • 86 Sehgal VN, Sehgal D, Syed NH, Sharma S (2017). Erythroderma: an association or a manifestation extraordinary of hyper Immunoglobulin E. Indian J Paediatr Dermatol 18: 306-309.
  • 87 Martins IS, Pessoa-Silva CL, Nouer SA, et al (2006). Endemic extended-spectrum beta-lactamase-producing Klebsiella pneumoniae at an intensive care unit: risk factors for colonization and infection. Microb Drug Resist 12: 50-58.
  • 88 Mohrenschlager M, Darsow U, Schnopp C, et al (2006). Atopic eczema: what's new? J Eur Acad Dermatol Venereol 20: 503–513.
  • 89 Scheinfeld NS, Tutrone WD, Weinberg JM, et al (2003). Phototherapy of atopic dermatitis. Clin Dermatol 21: 241–248.
  • 90 Akdis CA, Akdis M, Bieber T, et al; European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology (2006). Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 118:152-169.
  • 91 Scheinfeld N (2005). Omalizumab: a recommbinat humanized monoclonal IgEblocking antibody. Dermatol Online J 11: 2.
  • 92 Betsi GI, Papadavid E, Falagas ME (2008). Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. Am J Clin Dermatol 9: 93–103.
  • 93 Yeşilova Y, Çalka O, Akdeniz N, Berktaş M (2012). Effect of probiotics on the treatment of children with atopic dermatitis. Ann Dermatol 24: 189–193.